Independent Assessment of the Process for the Review of Device Submissions; High Priority Recommendations, 75571-75572 [2013-29612]
Download as PDF
Federal Register / Vol. 78, No. 239 / Thursday, December 12, 2013 / Notices
currently collects data on the sale and
distribution of antimicrobial drugs
intended for use in food-producing
animals, as well as data on
antimicrobial resistance among
foodborne pathogens as part of the
National Antimicrobial Resistance
Monitoring System. FDA is currently
working in collaboration with other
agencies, including United States
Department of Agriculture and the
Centers for Disease Control, to explore
approaches for enhancing current data
collection efforts in order to measure the
effectiveness of the strategy. FDA
anticipates seeking additional public
input as it develops these
enhancements.
Dated: December 9, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
II. Significance of Guidance
AGENCY:
I. Background
maindgalligan on DSK5TPTVN1PROD with NOTICES
addressed adhesive label to assist that
office in processing your requests. See
the SUPPLEMENTARY INFORMATION section
for electronic access to the guidance
document.
Submit electronic comments on the
guidance to https://www.regulations.gov.
Submit written comments to the
Division of Dockets Management (HFA–
305), Food and Drug Administration,
5630 Fishers Lane, Rm. 1061, Rockville,
MD 20852.
FOR FURTHER INFORMATION CONTACT:
William T. Flynn, Center for Veterinary
Medicine (HVF–1), Food and Drug
Administration, 7519 Standish Pl.,
Rockville, MD 20855, 240–276–9084,
email: william.flynn@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
This level 1 guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The guidance represents the Agency’s
current thinking on the topic. It does not
create or confer any rights for or on any
person and does not operate to bind
FDA or the public. An alternative
approach may be used if such approach
satisfies the requirements of the
applicable statutes and regulations.
ACTION:
75571
In the Federal Register of April 13,
2012 (77 FR 22327), FDA published the
notice of availability for a draft guidance
entitled ‘‘New Animal Drugs and New
Animal Drug Combination Products
Administered in or on Medicated Feed
or Drinking Water of Food-Producing
Animals: Recommendations for Drug
Sponsors for Voluntarily Aligning
Product Use Conditions With GFI
#209,’’ giving interested persons until
July 12, 2012, to comment on the draft
guidance. FDA received numerous
comments on the draft guidance and
those comments were considered as the
guidance was finalized. In addition,
editorial changes were made to improve
clarity. The guidance announced in this
notice finalizes the draft guidance dated
April 13, 2012.
The purpose of this guidance
document is to provide information to
sponsors of certain antimicrobial new
animal drug products who are interested
in revising conditions of use for those
products consistent with FDA’s
Guidance for Industry (GFI) #209, ‘‘The
Judicious Use of Medically Important
Antimicrobial Drugs in Food-Producing
Animals,’’ and to set timelines for
stakeholders wishing to comply
voluntarily with this guidance. FDA
intends to work with affected drug
sponsors to help them to voluntarily
implement the principles described
above through modifications to the
approved conditions of use of their new
animal drug products. FDA believes a
voluntary approach, conducted in a
cooperative and timely manner, is the
most effective approach to achieve the
common goal of more judicious use of
medically important antimicrobials in
animal agriculture.
FDA recognizes that it is important to
identify ways to assess the effect of GFI
#209 and GFI #213 over time. FDA
VerDate Mar<15>2010
16:45 Dec 11, 2013
Jkt 232001
This guidance refers to previously
approved collections of information
found in FDA regulations. These
collections of information are subject to
review by the Office of Management and
Budget (OMB) under the Paperwork
Reduction Act of 1995 (44 U.S.C. 3501–
3520). The collections of information in
21 CFR part 514 have been approved
under OMB control numbers 0910–0032
and 0910–0669.
IV. Comments
Interested persons may submit either
electronic comments regarding this
document to https://www.regulations.gov
or written comments to the Division of
Dockets Management (see ADDRESSES). It
is only necessary to send one set of
comments. Identify comments with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday, and
will be posted to the docket at https://
www.regulations.gov.
V. Electronic Access
Persons with access to the Internet
may obtain the guidance at either
https://www.fda.gov/AnimalVeterinary/
GuidanceComplianceEnforcement/
GuidanceforIndustry/default.htm or
https://www.regulations.gov.
Frm 00029
Fmt 4703
Sfmt 4703
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–N–1504]
Independent Assessment of the
Process for the Review of Device
Submissions; High Priority
Recommendations
Food and Drug Administration,
HHS.
III. Paperwork Reduction Act of 1995
PO 00000
[FR Doc. 2013–29697 Filed 12–11–13; 8:45 am]
Notice.
The Food and Drug
Administration (FDA) is presenting
Booz Allen Hamilton’s high priority
recommendations submitted as part of
their independent assessment of the
process for the review of medical device
submissions. The assessment is part of
the FDA performance commitments
relating to the Medical Device User Fee
Amendments of 2012 (MDUFA III),
which reauthorized device user fees for
fiscal years 2013 to 2017. The
assessment is described in section V,
‘‘Independent Assessment of Review
Process Management’’, of the
commitment letter entitled ‘‘MDUFA
Performance Goals and Procedures’’ 1
(MDUFA III Commitment Letter). The
assessment is being conducted in two
phases. The high priority
recommendations are the first of a series
of deliverables, as outlined in the
contract statement of work,2 to be
published as part of Phase 1 of the
assessment.
FOR FURTHER INFORMATION CONTACT:
Amber Sligar, Office of Planning, Food
and Drug Administration, 10903 New
Hampshire Ave., Bldg. 32, rm. 3291,
Silver Spring, MD 20993–0002, 301–
796–9384, Amber.Sligar@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
I. Background
On July 9, 2012, President Obama
signed into law the Food and Drug
Administration Safety and Innovation
Act (Pub. L. 112–144) (FDASIA).3 Title
1 www.fda.gov/downloads/MedicalDevices/
NewsEvents/WorkshopsConferences/
UCM295454.pdf.
2 https://www.fda.gov/MedicalDevices/Device
RegulationandGuidance/Overview/MDUFAIII/
ucm314036.htm.
3 https://www.gpo.gov/fdsys/pkg/PLAW–
112publ144/pdf/PLAW–112publ144.pdf.
E:\FR\FM\12DEN1.SGM
12DEN1
75572
Federal Register / Vol. 78, No. 239 / Thursday, December 12, 2013 / Notices
II of FDASIA is MDUFA III, which gives
FDA the authority to collect device user
fees from industry for fiscal years 2013
to 2017. MDUFA III took effect on
October 1, 2012, and will continue
through September 30, 2017.
Device user fees were first established
by Congress in 2002. Medical device
companies pay fees to FDA when they
register their establishment and list their
devices with the Agency, whenever they
submit an application or a notification
to market a new medical device in the
United States, and for certain other
types of submissions. Under MDUFA III,
FDA is authorized to collect user fees
that will total approximately $595
million (plus adjustments for inflation)
over 5 years. With this additional
funding, FDA will be able to hire more
than 200 full-time-equivalent workers
over the course of MDUFA III. In
exchange, FDA has committed to meet
certain performance goals outlined in
the MDUFA III Commitment Letter.4
maindgalligan on DSK5TPTVN1PROD with NOTICES
II. Assessment of FDA’s Process for the
Review of Device Submissions
Section V of the MDUFA III
Commitment Letter states that FDA and
the device industry will participate in a
comprehensive assessment of the
process for the review of device
applications. The assessment will
include consultation with both FDA and
industry. The assessment will be
conducted in two phases by a private,
independent consulting firm, under
contract with FDA, that is capable of
performing the technical analysis,
management assessment, and program
evaluation tasks required to address the
assessment as described in the MDUFA
III Commitment Letter.
FDA awarded the contract in June
2013 to the consulting firm Booz Allen
Hamilton. Findings on high-priority
recommendations (i.e., those likely to
have a significant impact on review
times) were scheduled to be published
within 6 months of award and are
included in the report available through
the link near the end of this notice.
Final comprehensive findings and
recommendations are scheduled to be
published within 1 year of contract
award. FDA agreed to publish an
implementation plan within 6 months
of receipt of each set of
recommendations. For Phase 2 of the
independent assessment, the contractor
will evaluate the implementation of
recommendations and publish a written
assessment no later than February 1,
2016.
4 www.fda.gov/downloads/MedicalDevices/News
The assessment includes, but is not
limited to, the following areas:
1. Identification of process
improvements and best practices for
conducting predictable, efficient, and
consistent premarket reviews that meet
regulatory review standards.
2. Analysis of elements of the review
process (including the presubmission
process, and investigational device
exemption, premarket notification
(510(k)), and premarket approval
application reviews) that consume or
save time to facilitate a more efficient
process. This includes analysis of root
causes for inefficiencies that may affect
review performance and total time to
decision. This will also include
recommended actions to correct any
failures to meet MDUFA goals. Analysis
of the review process will include the
impact of combination products,
companion diagnostic products, and
laboratory developed tests on the review
process.
3. Assessment of FDA methods and
controls for collecting and reporting
information on premarket review
process resource use and performance.
4. Assessment of effectiveness of
FDA’s Reviewer Training Program
implementation.
5. Recommendations for ongoing
periodic assessments and any
additional, more detailed, or focused
assessments.
FDA will incorporate findings and
recommendations, as appropriate, into
its management of the premarket review
program. FDA will analyze the
recommendations for improvement
opportunities identified in the
assessment, develop and implement a
corrective action plan, and assure its
effectiveness. FDA also will incorporate
the results of the assessment into a Good
Review Management Practices (GRMP)
guidance document. FDA’s
implementation of the GRMP guidance
will include initial and ongoing training
of FDA staff, and periodic audits of
compliance with the guidance.
The contractor’s Phase 1 findings on
high priority recommendations are
available at https://www.fda.gov/Medical
Devices/DeviceRegulationandGuidance/
Overview/MDUFAIII/ucm314036.htm.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: December 6, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013–29612 Filed 12–6–13; 8:45 am]
Dated: December 6, 2013.
Anna Snouffer,
Deputy Director, Office of Federal Advisory
Committee Policy.
BILLING CODE 4160–01–P
[FR Doc. 2013–29613 Filed 12–11–13; 8:45 am]
Events/WorkshopsConferences/UCM295454.pdf.
VerDate Mar<15>2010
16:45 Dec 11, 2013
Jkt 232001
National Institutes of Health
Center For Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Obesity,
Insulin Action, and Metabolic Dysfunction.
Date: January 9, 2014.
Time: 9:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Reed A Graves, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6166,
MSC 7892, Bethesda, MD 20892, (301) 402–
6297, gravesr@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Immune and Radiotherapy.
Date: January 16, 2014.
Time: 9:30 a.m. to 12:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Lawrence Ka-Yun Ng,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6152,
MSC 7804, Bethesda, MD 20892, 301–435–
1719, ngkl@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
BILLING CODE 4140–01–P
PO 00000
Frm 00030
Fmt 4703
Sfmt 9990
E:\FR\FM\12DEN1.SGM
12DEN1
Agencies
[Federal Register Volume 78, Number 239 (Thursday, December 12, 2013)]
[Notices]
[Pages 75571-75572]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-29612]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2013-N-1504]
Independent Assessment of the Process for the Review of Device
Submissions; High Priority Recommendations
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is presenting Booz
Allen Hamilton's high priority recommendations submitted as part of
their independent assessment of the process for the review of medical
device submissions. The assessment is part of the FDA performance
commitments relating to the Medical Device User Fee Amendments of 2012
(MDUFA III), which reauthorized device user fees for fiscal years 2013
to 2017. The assessment is described in section V, ``Independent
Assessment of Review Process Management'', of the commitment letter
entitled ``MDUFA Performance Goals and Procedures'' \1\ (MDUFA III
Commitment Letter). The assessment is being conducted in two phases.
The high priority recommendations are the first of a series of
deliverables, as outlined in the contract statement of work,\2\ to be
published as part of Phase 1 of the assessment.
---------------------------------------------------------------------------
\1\ www.fda.gov/downloads/MedicalDevices/NewsEvents/WorkshopsConferences/UCM295454.pdf.
\2\ https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/MDUFAIII/ucm314036.htm.
FOR FURTHER INFORMATION CONTACT: Amber Sligar, Office of Planning, Food
and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, rm. 3291,
---------------------------------------------------------------------------
Silver Spring, MD 20993-0002, 301-796-9384, Amber.Sligar@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
On July 9, 2012, President Obama signed into law the Food and Drug
Administration Safety and Innovation Act (Pub. L. 112-144) (FDASIA).\3\
Title
[[Page 75572]]
II of FDASIA is MDUFA III, which gives FDA the authority to collect
device user fees from industry for fiscal years 2013 to 2017. MDUFA III
took effect on October 1, 2012, and will continue through September 30,
2017.
---------------------------------------------------------------------------
\3\ https://www.gpo.gov/fdsys/pkg/PLAW-112publ144/pdf/PLAW-112publ144.pdf.
---------------------------------------------------------------------------
Device user fees were first established by Congress in 2002.
Medical device companies pay fees to FDA when they register their
establishment and list their devices with the Agency, whenever they
submit an application or a notification to market a new medical device
in the United States, and for certain other types of submissions. Under
MDUFA III, FDA is authorized to collect user fees that will total
approximately $595 million (plus adjustments for inflation) over 5
years. With this additional funding, FDA will be able to hire more than
200 full-time-equivalent workers over the course of MDUFA III. In
exchange, FDA has committed to meet certain performance goals outlined
in the MDUFA III Commitment Letter.\4\
---------------------------------------------------------------------------
\4\ www.fda.gov/downloads/MedicalDevices/NewsEvents/WorkshopsConferences/UCM295454.pdf.
---------------------------------------------------------------------------
II. Assessment of FDA's Process for the Review of Device Submissions
Section V of the MDUFA III Commitment Letter states that FDA and
the device industry will participate in a comprehensive assessment of
the process for the review of device applications. The assessment will
include consultation with both FDA and industry. The assessment will be
conducted in two phases by a private, independent consulting firm,
under contract with FDA, that is capable of performing the technical
analysis, management assessment, and program evaluation tasks required
to address the assessment as described in the MDUFA III Commitment
Letter.
FDA awarded the contract in June 2013 to the consulting firm Booz
Allen Hamilton. Findings on high-priority recommendations (i.e., those
likely to have a significant impact on review times) were scheduled to
be published within 6 months of award and are included in the report
available through the link near the end of this notice. Final
comprehensive findings and recommendations are scheduled to be
published within 1 year of contract award. FDA agreed to publish an
implementation plan within 6 months of receipt of each set of
recommendations. For Phase 2 of the independent assessment, the
contractor will evaluate the implementation of recommendations and
publish a written assessment no later than February 1, 2016.
The assessment includes, but is not limited to, the following
areas:
1. Identification of process improvements and best practices for
conducting predictable, efficient, and consistent premarket reviews
that meet regulatory review standards.
2. Analysis of elements of the review process (including the
presubmission process, and investigational device exemption, premarket
notification (510(k)), and premarket approval application reviews) that
consume or save time to facilitate a more efficient process. This
includes analysis of root causes for inefficiencies that may affect
review performance and total time to decision. This will also include
recommended actions to correct any failures to meet MDUFA goals.
Analysis of the review process will include the impact of combination
products, companion diagnostic products, and laboratory developed tests
on the review process.
3. Assessment of FDA methods and controls for collecting and
reporting information on premarket review process resource use and
performance.
4. Assessment of effectiveness of FDA's Reviewer Training Program
implementation.
5. Recommendations for ongoing periodic assessments and any
additional, more detailed, or focused assessments.
FDA will incorporate findings and recommendations, as appropriate,
into its management of the premarket review program. FDA will analyze
the recommendations for improvement opportunities identified in the
assessment, develop and implement a corrective action plan, and assure
its effectiveness. FDA also will incorporate the results of the
assessment into a Good Review Management Practices (GRMP) guidance
document. FDA's implementation of the GRMP guidance will include
initial and ongoing training of FDA staff, and periodic audits of
compliance with the guidance.
The contractor's Phase 1 findings on high priority recommendations
are available at https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/MDUFAIII/ucm314036.htm.
Dated: December 6, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013-29612 Filed 12-6-13; 8:45 am]
BILLING CODE 4160-01-P